The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

Intellia faces backlash after halting drug work and layoffs, despite strategic decisions to focus on best ideas. Click here to find out why NTLA is a Sell.

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Intellia Therapeutics (NTLA – Research ...

Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $10.2 which represents a decrease of $-1.82 or -15.14% from the prior close of $12.02. The stock opened at $11.24 and touched a ...

NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

周一，Oppenheimer调整了对Intellia Therapeutics (NASDAQ:NTLA)股票的展望，将公司的目标价从之前的60.00美元下调至40.00美元。尽管目标价下调，但该公司仍维持对这家生物技术公司股票的"优于大市"评级。这一决定是在Intellia Therapeutics宣布战略调整和裁员以延长财务周期后做出的。

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report published ...

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO ...